TNF and breast cancer: Jinesh and colleagues found that the SMAC mimetic compound-C was able to sensitize BC cells to BCG-stimulated neutrophils, which constitute the main type of immune cells recruited in response to BCG treatment to release TNF-α, TRAIL and FasL.